메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Qiming Venture Partners Donates HK$3 Million to Tai Po Wang…

SHANGHAI, Nov. 30, 2025 -- On the afternoon of November 26, a major Grade 5 fire spread across multiple residential buildings in Wang Fuk Court in Tai Po, Hong Kong, causing severe casualties and drawing widespread public concern. In response, on November 28, Qiming Venture Partners made a donation of HK$3 million to the Tai Po Wang Fuk Court Aid Fund established by the Hong Kong SAR Government, to support affected residents and contribute to post-disaster reconstruction. The Hong Kong SAR Government established the Tai Po Wang Fuk Court Aid Fund on November 27, with an initial allocat
- 김갑성 기자
- 2025-11-30 07:17
텐룽, 2025 세계 에이즈의 날에 혁신적 혈액 검사 솔루션 공개...수혈 안전 강화에 일익

[ 메디채널 김갑성 기자 ] 시안, 중국 2025년 11월 29일 -- 텐룽(Tianlong)이 2025년 세계 에이즈의 날을 맞아 일체형 핵산 혈액 검사 솔루션을 공개하면서 더 진보한 전 세계 수혈 안전성에 대한 헌신을 다시 한번 천명했다. 이 솔루션은 고감도 NAT 시약을 고도로 자동화해 결합한 제품으로 저바이러스 부하 감염을 조기에 검출하는 역할을 한다. 이는 수혈로 인한 HIV 감염을 줄이고 안전한 혈액이 필요한 환자를 보호하는 데 필수적인 단계다. 조기 발견으로 혈액 안전성 강화 혈액 안전성 확보는 수혈로 인한 감염을 가장 효과적으로 막는 수단이다. 텐룽은 검사 정확도를 높이고 실험실에서 HBV, HCV, HIV-1, HIV-2를 조기에 발견해 전 세계 공중 보건 활동을 지원하는 한편 헌혈 받은 혈액에 대한 신뢰도를 높이고 있다. 혈액 스크리닝 적용을 위한 완전 자동화 워크플로 텐룽 솔루션의 핵심은 혈액 센터와 대규모 스크리닝 프로그램에 맞춰 개발한 Aurora PANA X6 전자동 핵산 추출 시스템이다. Gentier 96 Real-time PCR System과 함께
- 김갑성 기자
- 2025-11-29 23:19
SpeQtre, the entanglement-based quantum comms demon…

SpeQtral-RAL Space Quantum Communications Satellite Successfully Launches on SpaceX Transporter-15 Singapore-UK quantum collaboration begins on-orbit commissioning following successful deployment SINGAPORE and OXFORDSHIRE, England, Nov. 29, 2025 -- SpeQtral, Singapore's leading quantum communications company, in partnership with the UK Science and Technology Facilities Council's (STFC) RAL Space, announces the successful launch and deployment of the SpeQtre CubeSat aboard SpaceX's Transporter-15 mission. The spacecraft, containing SpeQtral's space-qualified entangled pho
- 김갑성 기자
- 2025-11-29 09:00
ANKH Pain Relief Health Group Donates HK$1 Million to the Hong…

HONG KONG, Nov. 29, 2025 -- In response to the devastating No. 5 alarm fire at Wang Fuk Court, Tai Po, ANKH Pain Relief Health Group has donated HK$1 million to the Hong Kong Red Cross to support their "Tai Po Fire Emergency Appeal". The major blaze at Wang Fuk Court has caused serious casualties and left thousands of residents homeless. The Hong Kong Red Cross has swiftly activated its emergency response mechanism to assist those affected, providing on-site first aid, emergency cash assistance, essential daily supplies, psychological support services, and post-disaster recov
- 김갑성 기자
- 2025-11-29 08:00
HEISR's Kickstarter-Favorite 3-Sided Toothbrush Returns to the…

LAS VEGAS, Nov. 28, 2025 -- The 3-sided electric toothbrush that gained strong support on Kickstarter in 2023 is officially returning to the U.S. this Black Friday. As more users seek practical upgrades to their everyday routines, HEISR reintroduces its patented wrap-around design known for deeper inner-surface cleaning, up to 75% faster brushing, and a noticeably gentler experience for sensitive gums. A New Approach to Everyday Oral Hygiene Rather than relying on stronger motors or additional modes, HEISR redesigned the brushing method itself. The patented wrap-around
- 김갑성 기자
- 2025-11-28 23:15
HZICC：Innovation hub: Hangzhou witness new voices and…

HANGZHOU, China, Nov. 28, 2025 -- The remarkable achievements of past winners of Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents have set a powerful example, inspiring a new wave of international innovators to bring their projects to Hangzhou. Among this year's competitors, Huang Yuanhui is an innovator from the Technical University of Munich, who introduced "NeuroMusician," a wearable device that modulates brainwaves to alleviate stress and improve sleep. "The device uses AI to help users achieve mental calmness and deeper sleep--all within
- 김갑성 기자
- 2025-11-28 21:25
HZICC：Unlocked potential: why global innovators choose H…

HANGZHOU, China, Nov. 28, 2025 -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured letters of intent totaling over RMB 2.5 billion. But his success extends beyond the competition. "As a Zhejiang native, Hangzhou's mix of strategic location, academic resources, and pro-innovation policies has made the city obviously attractive," Meng reflects. Since winning,
- 김갑성 기자
- 2025-11-28 21:19
BioDlink Showcases Europe-China CMC Collaboration Amid De…

Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end CMC platform SUZHOU, China, Nov. 28, 2025 -- BioDlink, a global leader in biologics contract development and manufacturing, took center stage at Biologics CDMO Europe 2025 to present its critical role in the regulatory approval and manufacturing support of the world's first approved EGF
- 김갑성 기자
- 2025-11-28 21:00
Angel Yeast's 8,500-Ton Specialty Yeast Facility and New Brew…

YICHANG, China, Nov. 28, 2025 -- Angel Yeast (SH600298), a global leader in yeast and fermentation solutions, has begun trial production at its new specialty yeast project in the Baiyang Biotechnology Park, Yichang High‑tech Zone. The facility commenced material feeding on August 31 and, once fully ramped, will reach an annual capacity of 8,500 tons. This launch completes Angel Yeast's full-chain layout in specialty yeast—from R&D and pilot‑scale production to scaled manufacturing—enhancing supply of high-value yeast‑derived ingredients for craft brewing, wine, and bioenergy, and
- 김갑성 기자
- 2025-11-28 20:58
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application…

BEIJING, Nov. 28, 2025 -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug marketing approval from the China National Medical Products Administration (NMPA). This approval is for the treatment of relapsed or refractory Large B-Cell Lymphoma (r/r LBCL) after two or more lines of systemic therapy. This is the second approved indication in China for Ina-cel, following its initial approval in
- 김갑성 기자
- 2025-11-28 20:52

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분